Remove Diabetes Remove Immunization Remove Presentation
article thumbnail

STAT+: Pharmalittle: We’re reading about compounders suing the FDA, Biogen turning to telehealth, and more

STAT

So join us as we hoist the ever-present cup of stimulation — our choice today is coconut rum — and attack the fast-growing to-do list. Lots of sunshine and clear blue skies are once again enveloping the Pharmalot campus, where the official mascots are bounding about the grounds in search of creatures to annoy. ” A U.S.

article thumbnail

Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?

Pharmaceutical Technology

On November 17, 2022, the FDA approved Provention Bio’s Tzield (teplizumab) , making it the first and only treatment to delay the onset of type 1 diabetes (T1D). Tzield’s approval brings the opportunity to explore how the drug can advance diabetes education, treatment, and management. “We Equity in early-stage testing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Retatrutide?

Pharmaceutical Technology

The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Retatrutide Overview Retatrutide (LY-3437943) is under development for the treatment of type 2 diabetes mellitus and obesity. million in FY2021.

article thumbnail

Risk adjusted net present value: What is the current valuation of Novartis’s Gevokizumab?

Pharmaceutical Technology

The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The post Risk adjusted net present value: What is the current valuation of Novartis’s Gevokizumab? appeared first on Pharmaceutical Technology.

article thumbnail

US FDA expands approval to GSK’s Arexvy for adults aged 50-59, at increased risk

Express Pharma

Adults with underlying medical conditions, such as chronic obstructive pulmonary disease (COPD), asthma, heart failure and diabetes (3) are at increased risk for severe consequences from an RSV infection compared to those without these conditions. RSV can exacerbate these conditions and lead to pneumonia, hospitalisation or death.(4)

Vaccines 111
article thumbnail

Advancing NOX inhibitors for treating fibrotic diseases and cancer

European Pharmaceutical Review

2 These are cells commonly found in the stroma of the tumour, which play an important role in inhibiting the body’s own immune response to the tumour, mediated through CD8+ T-cells (tumour-infiltrating lymphocytes). This includes Glucox Biotech’s GLX7013114, which inhibits NOX4 and is in development for diabetic retinopathy.

article thumbnail

Developing a new treatment paradigm for chronic kidney disease

European Pharmaceutical Review

This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). This leads to the formation of immune complexes that deposit in the glomerulus and result in haematuria, proteinuria, and decline in kidney function.